Eureka Therapeutics Announces Upcoming Conference Presentations in March 2020

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that the company is scheduled to present at the following March healthcare conferences:

Cowen 40^th Annual Health Care Conference
Title: ARTEMIS^® Antibody TCR T Cell Therapies for Solid Tumors
Speaker: Hanzhong Li, Ph.D., Senior Vice President of Corporate Strategy
Location: Boston Marriott Copley Place, Boston, MA
Date: Wednesday, March 4, 2020
Time: 8:30 a.m. EST

BioProcess International US West
Title: Optimizing Viral Vector Production
Speaker: Nicole Nunez, Ph.D., Process Development Scientist
Location: Santa Clara Convention Center, Santa Clara, CA
Date: Wednesday, March 11, 2020
Time: 1:05 p.m. PST

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® AbTCR T cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005133/en/